Key Stats for Tempus Stock
- Total returns: 104%
- Current Share Price: $63
- 52-Week High: $91
- Tempus AI Stock Price Target: $62
What Happened?
Tempus AI (TEM), valued at a market cap of $10.8 billion, is among the most popular stocks in the artificial intelligence space and is also part of Nancy Pelosi’s stock portfolio.
According to the Nancy Pelosi stock tracker, the former House Speaker purchased 50 call options in Tempus AI stock in early 2025. The AI stock went public in June 2024 and has since doubled in market value over the past 11 months.
Tempus AI stock continues to move higher after the healthcare AI company recently announced a three-year, $200 million data and modeling license agreement with pharmaceutical giant AstraZeneca and Pathos AI.
This strategic partnership aims to develop an artificial intelligence model for oncology that will help generate clinical insights, aid in the discovery of new drug targets, and accelerate treatment development.
The partnership news follows Tempus AI’s impressive Q1 results, which showed a 75.4% year-over-year increase in revenue to $255.7 million, driven by an 89% surge in its genomics segment.
Additionally, Tempus raised its full-year 2025 revenue guidance to $1.25 billion, representing approximately 80% growth from the previous year.
Tempus AI stock has now climbed 86% year-to-date, dramatically outperforming the broader market’s 0.5% decline during the same period.
See Tempus AI’s full Q1 earnings transcript (It’s free) >>>
What the Market Is Telling Us About Tempus AI Stock
The strong performance of Tempus AI stock reflects growing investor confidence in the company’s position at the intersection of artificial intelligence and precision medicine.
As one of the largest sequencers of cancer patients in the United States with connections to approximately 3,000 provider sites, Tempus AI has built what it considers “one of the largest libraries of clinical and molecular oncology data in the world.”
Despite ongoing challenges like negative adjusted EBITDA ($16.2 million loss, though improved from $43.9 million a year ago) and reimbursement issues for its minimal residual disease (MRD) assays, investors appear focused on its long-term potential.
The recent acquisition of Ambry Genetics for $600 million has strengthened TEM stock’s position in hereditary cancer testing, while new innovations like Tempus Loop aim to help pharmaceutical companies reduce R&D spending by more efficiently identifying new cancer treatment targets.
However, the significant premium on Tempus AI stock suggests that investors should approach it cautiously.
While Tempus shows tremendous promise as an early, specialized leader in healthcare AI software, its heavily forward-looking valuation indicates that TEM stock is likely best suited for investors with high risk tolerance willing to weather potential volatility in the months ahead.
Find the best stocks to buy today that are even better than Tempus AI. (It’s free) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
